Collaborations & Alliances

Phenomic, Boehringer Enter Strategic Oncology Alliance

Includes licensing options based on targets to be identified with Phenomic’s discovery platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Phenomic AI entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers leveraging Phenomic’s scTx single-cell transcriptomics platform to enhance Boehringer’s efforts to develop first-in-class medicines to treat cancer.   Stroma-rich cancers, such as colorectal and pancreatic cancers, are amongst the hardest to treat in part because of the tumor stroma: a complex tissue that protects cancerous cells from therapi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters